title: Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
authors.forename: U
authors.initials: U
authors.lastname: Keilholz
authors.forename: H
authors.initials: H
authors.lastname: Szelényi
authors.forename: J
authors.initials: J
authors.lastname: Siehl
authors.forename: H D
authors.initials: HD
authors.lastname: Foss
authors.forename: W
authors.initials: W
authors.lastname: Knauf
authors.forename: E
authors.initials: E
authors.lastname: Thiel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000032:analysis / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage / Q000031:analogs & derivatives; D006689:Hodgkin Disease / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007069:Ifosfamide / Q000008:administration & dosage; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007376:Interleukin-2; D003561:Cytarabine; D001761:Bleomycin; D011344:Procarbazine; D000069283:Rituximab; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D007069:Ifosfamide; D011241:Prednisone; D015255:Idarubicin